[{"id":"6f0e8964-6b0b-4d78-b6bc-84d0fc5f439c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01033032","created_at":"2021-01-18T04:03:22.301Z","updated_at":"2025-02-25T14:31:33.061Z","phase":"Phase 1/2","brief_title":"Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer","source_id_and_acronym":"NCT01033032","lead_sponsor":"SCRI Development Innovations, LLC","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calsed (amrubicin)"],"overall_status":"Completed","enrollment":" Enrollment 78","initiation":"Initiation: 12/01/2009","start_date":" 12/01/2009","primary_txt":" Primary completion: 07/01/2013","primary_completion_date":" 07/01/2013","study_txt":" Completion: 10/01/2014","study_completion_date":" 10/01/2014","last_update_posted":"2022-05-03"},{"id":"c62e60e1-8788-4244-9df9-2022af61d3c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03253068","created_at":"2021-01-18T16:04:13.891Z","updated_at":"2025-02-25T16:06:44.121Z","phase":"Phase 2","brief_title":"Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer","source_id_and_acronym":"NCT03253068","lead_sponsor":"Wakayama Medical University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Calsed (amrubicin)"],"overall_status":"Unknown status","enrollment":" Enrollment 25","initiation":"Initiation: 08/01/2017","start_date":" 08/01/2017","primary_txt":" Primary completion: 12/28/2020","primary_completion_date":" 12/28/2020","study_txt":" Completion: 12/31/2020","study_completion_date":" 12/31/2020","last_update_posted":"2020-05-19"}]